Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HLA-G/CD3 bispecific antibody RO7515629

A bispecific antibody targeting the tumor-associated antigen (TAA) histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on T lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody RO7515629 targets and binds to both CD3 on cytotoxic T lymphocytes (CTLs) and HLA-G found on HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor cell types and plays a key role in cancer immune evasion. It inhibits the immune responses by binding to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T and B lymphocytes, and dendritic cells (DCs).
Synonym:anti-HLA-G T-cell engager RO7515629
CD3-binding T-cell engager RO7515629
HLA-G TCB RO7515629
HLA-G-TCB RG6353
T-cell bispecific antibody RO7515629
TCB RO7515629
TCE RO7515629
Code name:RG 6353
RG-6353
RG6353
RO 7515629
RO-7515629
RO7515629
Search NCI's Drug Dictionary